Teijin's Novel Gout Drug To Launch In Europe
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Teijin Pharma will launch xanthine oxidase inhibitor TMX67, its novel gout drug, in Europe, the company announced Feb. 25.The Tokyo-based company received a positive recommendation Feb. 21 from the European Medicines Agency's Committee for Medicinal Products for Human Use
You may also be interested in...
Takeda’s Febuxostat Gets U.S. FDA Advisory Committee Nod for Gout; Cardio Risk Remains A Concern
A U.S. FDA advisory committee voted in favor of approving Takeda's gout therapy febuxostat during a Nov. 24 meeting, but strongly encouraged the agency to use its post-approval authorities to further explore a potential cardiovascular signal detected in clinical trials
Takeda’s Febuxostat Gets U.S. FDA Advisory Committee Nod for Gout; Cardio Risk Remains A Concern
A U.S. FDA advisory committee voted in favor of approving Takeda's gout therapy febuxostat during a Nov. 24 meeting, but strongly encouraged the agency to use its post-approval authorities to further explore a potential cardiovascular signal detected in clinical trials
Takeda’s Febuxostat Finally Gets U.S. Advisory Panel Review
Takeda North America's long-delayed investigational gout drug febuxostat, previously the subject of two "approvable" letters, will be reviewed by the U.S. FDA Arthritis Drugs Advisory Committee on Nov. 24